MedTrace Logo

Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19

NCT05166876 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-11-07

Study results available
· View outcomes & findings →

Summary

A Phase 2 multi-center, assessor-blind, randomized study to assess the safety, tolerability, and antiviral activity of brequinar in combination with dipyridamole.

Conditions

Interventions

DRUG

Brequinar Sodium

50 mg, 100 mg, 150 mg, 200 mg x 5 days

DRUG

Dipyridamole 75 MG

75 mg TID for 5 days

DRUG

Placebo

50 mg, 100 mg, 150 mg, 200 mg x 5 days

Sponsors & Collaborators

  • Clear Creek Bio, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2022-06-04
Completion
2022-06-04
FDA Drug
Yes

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05166876 on ClinicalTrials.gov